Core Viewpoint - The article discusses the comprehensive deployment of China's 15th Five-Year Plan, emphasizing the development of a modern industrial system, a strong domestic market, and coordinated regional development, with a particular focus on emerging industries like brain-machine interfaces [2][3][4]. Industry Development - The 15th Five-Year Plan aims to cultivate new pillar industries, with a focus on future industries such as quantum technology, bio-manufacturing, hydrogen energy, nuclear fusion, brain-machine interfaces, embodied intelligence, and 6G mobile communication [3][4]. - Brain-machine interface technology is highlighted for its potential to transform economic structures and improve societal welfare, enabling applications in medical rehabilitation, industrial manufacturing, and consumer electronics [3][4]. Policy Support - The brain-machine interface has been officially recognized as a future industry by the Ministry of Industry and Information Technology and other departments, marking its entry into national strategic planning [4][5]. - The "Implementation Opinions" released in July 2025 set clear goals for the brain-machine interface industry, aiming for breakthroughs in core technologies by 2027 and positioning the industry among the world's leaders by 2030 [4][5]. Market Potential - The brain-machine interface industry is projected to create a market scale in the hundreds of billions, generating numerous high-skilled job opportunities and establishing a new competitive advantage for China in global technology [6][7]. - The industry is expected to evolve towards more precise, safer, and more accessible technologies during the 15th Five-Year Plan, with significant advancements in hardware and software capabilities [6][7]. Commercial Applications - Companies are actively engaging in the brain-machine interface space, with various business models targeting both B2B and B2C markets, including medical rehabilitation and consumer electronics [7][8]. - Examples of commercial initiatives include partnerships for developing implantable systems, clinical transformation centers, and innovative products like brain-controlled games and smart mattresses [7][8]. Conclusion - The emphasis on brain-machine interfaces in the 15th Five-Year Plan signifies a shift from following to leading in this technology, aligning with China's development philosophy centered on improving human welfare [8].

Core Insights - The year 2025 is anticipated to be a pivotal year for brain-computer interfaces (BCIs), with rapid advancements and significant capital influx into the sector [1][9] - The integration of AI and BCIs is seen as a potential game-changer, with both technologies expected to converge and enhance each other [9][32] Investment and Development - Brain Tiger Technology, founded by Tao Hu, received early angel investment of 30 million yuan from Chen Tianqiao, who has been a key supporter throughout its development [3][25] - The BCI industry has seen a compound annual growth rate of over 30% in financing events from 2018 to 2024, with 20 new financing events in Q3 2025 alone [9][29] Technological Advancements - Brain Tiger has developed a high-throughput, implantable flexible BCI that can decode both motor and language signals in real-time, making it the only company globally with this dual capability [4][6] - The company has conducted 53 short-term clinical trials and is set to initiate the world's first long-term clinical trial of a fully wireless, fully implanted, and fully functional flexible cortical BCI [9][14] Clinical Applications - BCIs are being utilized in clinical settings to assist disabled patients in controlling prosthetic limbs and enabling communication for those with speech impairments [4][6] - Recent trials have demonstrated the ability of BCIs to decode neural signals into coherent language, allowing patients to communicate thoughts without verbalizing [6][18] Market Landscape - The global BCI market was valued at $1.2 billion in 2019 and is projected to reach $2.48 billion by 2024, primarily driven by medical applications [23] - Major players in the industry, including OpenAI and Meta, are recognizing the potential of BCIs, leading to increased competition and investment [9][32] Future Vision - Tao Hu envisions BCIs evolving from merely restoring normal function to enhancing human capabilities beyond physical limits, aiming for a future where humans can possess AI-like abilities [9][32] - The long-term strategy for Brain Tiger includes three phases: commercializing research applications, obtaining medical device certifications, and building an ecosystem that connects BCIs with AI and other technologies [23][24]

Investment Rating - The report maintains an "Outperform" rating for the brain-computer interface (BCI) industry [1] Core Insights - The brain-computer interface industry is rapidly developing, enabling direct communication between the brain and external devices, with significant advancements in technology and market potential [2][3] - China holds multiple advantages in developing the BCI industry, including technological leadership in non-invasive interfaces, a growing industrial base, and increasing market demand driven by an aging population and industrial upgrades [22][18] - The BCI technology involves four core steps: neural signal acquisition, signal processing and feature extraction, decoding and machine learning, and feedback and control [27][24] - The BCI industry has a complete supply chain covering upstream (materials, chips, electrodes), midstream (signal acquisition and processing), and downstream (medical health, consumer life, industrial production) applications [58][71] Summary by Sections Industry Investment Rating - The report maintains an "Outperform" rating for the BCI industry [1] Industry Overview - The BCI technology allows for a new communication channel between the brain and external devices, with applications expanding due to advancements in neuroscience and artificial intelligence [2][3] - The global BCI market is projected to grow from approximately $2.62 billion in 2024 to $2.94 billion in 2025, and is expected to reach $12.4 billion by 2034 [2] Technological Development - BCI technology is evolving through three main paths: invasive, semi-invasive, and non-invasive methods, each with distinct advantages and applications [28][30] - Invasive interfaces provide the most precise neural signal acquisition but come with higher risks, while non-invasive interfaces are safer and more user-friendly [41][45] Market Applications - The BCI industry is witnessing rapid growth in various application scenarios, including medical rehabilitation, consumer electronics, and industrial production [58][71] - The medical health sector is currently the largest application area for BCI technology, accounting for approximately 47.62% of the market, with significant potential in rehabilitation and neurodiagnostics [71]

Core Insights - The rapid development of brain-computer interface (BCI) technology is transforming the concept of "brain control" from science fiction to reality, with significant advancements expected by 2025 [2] Group 1: BCI Technology Developments - BCI technology establishes a direct communication channel between the biological brain and intelligent machines, enabling the decoding of brain signals and control of external devices [3] - Neuralink, a company backed by Elon Musk, plans to implant devices in the speech cortex by Q4 2025 to decode silent "intent speech," with further developments aimed at restoring vision for the blind by 2026 and achieving multi-device implants by 2027 [3] - Synchron, another leading BCI company, successfully completed a minimally invasive BCI procedure for 10 patients by the end of 2024, allowing them to control smart devices through thought [3] Group 2: China's BCI Progress - China has made significant strides in BCI technology, becoming the second country globally to enter the clinical trial phase for invasive BCI technology, with a successful trial involving a patient who regained functionality after an accident [4] - The Chinese government has set ambitious goals for BCI technology, aiming for breakthroughs in key technologies by 2027 and the establishment of industry standards for BCI medical devices [4] Group 3: Global Competitive Landscape - The BCI technology sector is highly concentrated in the U.S., with a few companies like Neuralink and Synchron leading the market, while China is rapidly catching up despite a later start [5] - Other countries, including those in the EU, Japan, South Korea, and Australia, are also accelerating their efforts in BCI technology to secure a competitive edge in global brain science [5] Group 4: Ethical and Regulatory Considerations - The rapid advancement of BCI technology has raised ethical concerns regarding privacy, "brain control," and equitable access to technology, prompting discussions among various stakeholders [6] - Guidelines have been established in China to ensure that BCI research focuses on enhancing human capabilities while minimizing potential harm and respecting individual autonomy [7]

Summary of Neuralink Conference Call Company Overview - **Company**: Neuralink - **Industry**: Brain-Computer Interface (BCI) - **Founders**: Elon Musk and a team of scientists and engineers - **Founded**: July 2016 - **Current Status**: Engaged in human trials with ongoing product development Key Points Industry Insights - **Emerging Field**: Neuralink is at the forefront of brain-computer implants (BCI), a rapidly evolving sector with significant implications for healthcare, gaming, social media, and defense [1][4][10] - **Market Potential**: The total addressable market (TAM) for BCI in the US is estimated at approximately $400 billion, with potential expansion into warfare and gaming applications [10][51] Product Development - **Telepathy**: The initial product allowing users to control computers with thoughts. As of September 2025, 12 patients have been implanted, with plans to increase to 25 by year-end. Initial usage averages 7.5 hours per day, with one patient exceeding 100 hours per week [15][25][37] - **Blindsight**: Aimed at restoring vision for those with partial or full blindness, expected to launch in 2030, with a projected annual revenue of over $500 million [26][53] - **Surgical Robot**: Neuralink employs a custom-built surgical robot for implanting devices, which significantly reduces the time required for insertion [35][36] Investment Implications - **Profound Opportunities**: The ability to control devices with thoughts opens new avenues for investment across various sectors, including healthcare and technology [4][51] - **Funding**: Neuralink has raised $1.34 billion as of September 2025, with a recent Series E round raising $650 million at a $9 billion valuation [51][54] Regulatory Landscape - **FDA Approval**: Neuralink received FDA approval for human trials in May 2023, with Breakthrough Device Designation for both Telepathy and Blindsight [36][58] - **Future Approvals**: Anticipated regulatory approvals for Telepathy by 2029 and Blindsight by 2030 [36][53] Competitive Landscape - **Major Competitors**: Key competitors include Synchron, Precision Neuroscience, and Paradromics, each with unique approaches to BCI technology [59][61][67] - **Global Ambitions**: China is investing heavily in BCI technology, aiming to establish a national industry to compete globally [72] Challenges and Risks - **Surgical Invasiveness**: Neuralink's approach is more invasive than competitors, which may pose risks and complications [45] - **Degradation of Implants**: Concerns about the longevity and effectiveness of implants, as evidenced by initial patient experiences [46] - **Societal Risks**: Potential for creating a class of 'neuro-elite' due to disparities in access to BCI technology [50][49] Future Goals - **Enhancing Human Capabilities**: Neuralink aims to provide cybernetic enhancements and understand consciousness, ultimately achieving human-AI symbiosis [22][24] - **Expansion Plans**: Plans to scale operations to implant 20,000 patients annually by 2031, generating $1 billion in revenue [53] Conclusion Neuralink is positioned as a leader in the BCI industry, with significant advancements in technology and a clear vision for the future. The potential for investment and societal impact is substantial, but challenges related to regulatory approval, surgical risks, and ethical considerations remain critical areas to monitor.

Core Viewpoint - Cognixion has initiated a clinical study to explore the integration of its non-invasive brain-computer interface (BCI) based on EEG with Apple Vision Pro, aiming to provide a new natural interaction method for patients without surgery [2][8] Product and Technology Features - Cognixion's Axon-R platform is a wearable, non-invasive neural interface device that captures and decodes brain activity through advanced EEG measurement and feedback [4] - The study combines Cognixion's platform with Apple Vision Pro's spatial computing and assistive features, emphasizing a "non-surgical, wearable, and everyday" approach, making it easier to promote in clinical and home settings [4][10] Clinical Research Design - The clinical study has begun recruitment and will continue until April 2026, with plans to conduct pivotal clinical trials and apply for FDA approval in 2026 after feasibility studies [5] Interaction and Application - The study aims to validate natural communication capabilities through the combination of EEG signals and eye-tracking, assessing the technology's value in mobile device control, entertainment, education, and work [6] - The focus is on exploring applications for patients with ALS, spinal cord injuries, post-stroke speech disorders, and traumatic brain injuries [6] Company and Collaboration Background - Cognixion, based in Santa Barbara, California, is a startup focused on neural interfaces and assistive technologies, aiming to make brain-computer interfaces accessible as wearable everyday devices [7] Industry Trends - The integration of non-invasive BCI technology with mainstream consumer electronics, represented by Cognixion's collaboration with Apple Vision Pro, signifies a new trend in the BCI market [8] - The opportunity for non-invasive BCI is highlighted as it provides a lower barrier solution compared to implantable BCIs, which are still in early clinical stages [10] - The trend towards multi-modal integration, combining EEG signals with eye-tracking and head posture, is seen as a significant development direction for future BCI technologies [10]

点击注册小程序 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 政策与技术双轮驱动，百亿蓝海市场加速开启 脑机接口作为生命科学与信息技术融合的前沿领域，已从实验室走向产业化临界点。全球市场规模从2019 年12亿美元增至2023年20亿美元，2029年预计达76.3亿美元。政策端七部门联合发布《关于推动脑机接口 产业创新发展的实施意见》，明确2027年技术突破、2030年产业生态成型的目标，叠加卒中、渐冻症等刚 需驱动，行业进入"政策-研发-应用"闭环，商业化路径逐渐清晰。 临床产品有望加速落地，医疗+消费打造行业双增长曲线 医疗是目前脑机产业下游商业应用最成熟、产业规模最大的行业，2024年国内临床试验达31项，覆盖卒中 康复、意识障碍、抑郁症等10类疾病。政策端医保定价打通支付链路，有望推动脑机接口相关设备落地 ...

Investment Rating - The report suggests focusing on companies with "technical barriers + clinical landing" as the dual main lines for investment, recommending attention to medical scene integrators and leaders in invasive technology [4]. Core Insights - The brain-computer interface (BCI) industry is driven by both policy and technology, with a market expected to grow from $1.2 billion in 2019 to $2 billion in 2023, and projected to reach $7.63 billion by 2029, indicating a compound annual growth rate (CAGR) of 17.5% from 2024 to 2029 [3][24]. - The medical sector is currently the most mature application area for BCI, with 31 clinical trials planned in 2024 covering various diseases, and the integration of medical and consumer applications is expected to create a dual growth curve [3][54]. - The domestic industry chain is becoming more self-sufficient, with significant advancements in invasive BCI technologies, and several regions are expected to form industrial clusters [4][27]. Summary by Sections Industry Overview - BCI technology is a frontier field at the intersection of life sciences and information technology, creating interactive systems between the brain and external devices [14][16]. - The global BCI market is projected to grow significantly, with a forecasted market size of $7.63 billion by 2029, reflecting a CAGR of 17.5% from 2024 to 2029 [24][25]. - The industry is currently in a technology validation phase, with active investment activities, particularly in China, where over 200 financing events have occurred, totaling nearly $2 billion [27][29]. Policy Guidance - The Chinese government has issued several policies to support the BCI industry, aiming for technological breakthroughs by 2027 and the establishment of a robust industrial ecosystem by 2030 [42][43]. - The regulatory framework is evolving, with ongoing efforts to ensure safety, effectiveness, and ethical compliance in BCI technology [45][47]. Clinical Situation - Stroke is identified as the primary indication for BCI applications, with a significant patient population in need of rehabilitation solutions [54][59]. - The number of clinical trials related to BCI is increasing, with 31 trials registered in 2024, indicating a growing interest in the clinical potential of BCI technologies [65][66].

Core Viewpoint - Vivani Medical is splitting its subsidiary Cortigent, allowing both companies to focus on their respective business areas, with Vivani concentrating on micro drug delivery systems and Cortigent on neural modulation and brain-computer interface technologies [4][14]. Group 1: Vivani's Split of Cortigent - Vivani announced the split plan in May 2025 and confirmed the record date in September, with shareholders receiving shares of Cortigent based on their holdings [4]. - The split aims to create two independent companies that can generate value in their respective fields, enhancing strategic flexibility and optimizing capital structures [4][14]. Group 2: Vivani's Business Focus - Post-split, Vivani will focus on implantable drug delivery systems, particularly long-acting GLP-1 drug delivery devices, and will expand into other chronic disease treatments [5][10]. - The company plans to collaborate with pharmaceutical firms to accelerate clinical progress and commercialization, aligning with the trend of long-term treatment and chronic disease management [10]. Group 3: Cortigent's Business Layout - Cortigent will focus on neural modulation and brain-computer interface (BCI) technologies, aiming to help patients restore critical physiological functions through implanted neural stimulation and visual prosthetics [6][13]. - The product pipeline includes a stroke rehabilitation system designed to assist stroke patients in regaining motor and sensory functions [8]. Group 4: Clinical and Regulatory Progress - The Orion system has completed a six-year follow-up feasibility study, showing safety and functional improvement potential in severely blind patients [9]. - Cortigent plans to initiate pivotal clinical trials for Orion to facilitate FDA approval and conduct early clinical research for the stroke rehabilitation system [18]. Group 5: Capital Operations and Strategic Implications - The split enhances strategic flexibility, allowing both companies to independently develop R&D and commercialization plans, thus avoiding resource dilution [14]. - Each company can design financing models suited to their business characteristics, with Vivani focusing on drug delivery and Cortigent seeking capital in the neural modulation and BCI markets [15]. - Shareholders will benefit from continued growth in Vivani while also gaining exposure to the emerging field of neural modulation and BCI through their ownership in Cortigent [16]. Group 6: Industry Context and Trends - The split reflects the increasing interest in brain-computer interfaces and neural modulation, with companies like Neuralink and Synchron gaining attention [20]. - Regulatory bodies, such as the FDA, are showing more support for implantable BCI systems, indicating a shift towards clinical implementation [20][21]. - The industry is moving from conceptual stages to serious industrialization and capitalization, with companies seeking to enhance strategic clarity and financing efficiency through specialization [21].

Core Viewpoint - The brain-computer interface (BCI) technology is advancing rapidly, with companies like Neuralink and Synchron making significant strides in clinical trials, aiming to restore lost functions in patients with paralysis or neurological diseases [1][2][3] Group 1: Current Developments in BCI Technology - Neuralink has completed craniotomy implants in a small number of patients, focusing on restoring motor and speech functions, with plans to conduct speech cortex experiments by Q4 2025 [1] - Synchron has validated the safety and partial recovery of daily functions for paralyzed patients through minimally invasive vascular implants [1] - The public is caught between two visions: one of hope for restoring lost functions and another fueled by tech leaders' marketing, leading to concerns about the implications of BCI technology [1][2] Group 2: Ethical Considerations and Limitations - High Xiaorong, a professor at Tsinghua University, emphasizes that BCI is not a shortcut to "superhuman" capabilities but rather a technology focused on repair and assistance under ethical constraints [2][3] - The concept of "superhumanization" raises ethical issues regarding fairness and accessibility, leading to a shift in focus towards clinical applications [3][4] Group 3: Potential Applications and Future Directions - BCI technology could facilitate human-machine collaboration, addressing communication gaps between human and artificial intelligence [4] - Possible applications include memory enhancement for Alzheimer's patients and aiding communication for those unable to speak [8][9] - The technology is expected to evolve, with advancements in AI playing a crucial role in processing large data sets generated by BCI devices [10] Group 4: Challenges and Research Landscape - Current challenges include hardware and software limitations, with a need for improved signal processing capabilities [10][12] - Clinical applications are primarily focused on medical fields, with potential expansions into elder care, cognitive rehabilitation, and emotional support [15] - The research landscape shows that China leads in non-invasive and semi-invasive studies, while the U.S. excels in invasive research [16] Group 5: Timeline for Maturity - The timeline for achieving mature BCI technology has been revised from an initial estimate of 60 years to a more optimistic 15 to 20 years, although significant limitations still exist [17][18]